StreetInsider.com News Articles

Genprex to Participate at BIO Europe Spring 2026

Tue, 10 Mar 2026 07:00:00 -0400

AUSTIN, Texas, March 10, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that members from its executive leadership team will be attending and participating at BIO Europe Spring taking place March 23-25, 2026 in Lisbon, Portugal.

Genprex to Participate at BIO Europe Spring 2026

Tue, 10 Mar 2026 07:00:00 -0400

Genprex to Participate at BIO Europe Spring 2026

Tue, 10 Mar 2026 07:00:00 -0400

Genprex to Participate at BIO Europe Spring 2026

Tue, 10 Mar 2026 07:00:00 -0400

Genprex to Participate at BIO Europe Spring 2026

Tue, 10 Mar 2026 07:00:00 -0400

Genprex to Participate at BIO Europe Spring 2026

Tue, 10 Mar 2026 07:00:00 -0400

Genprex to Participate at BIO Europe Spring 2026

Tue, 10 Mar 2026 07:00:00 -0400

Genprex to Participate at BIO Europe Spring 2026

Tue, 10 Mar 2026 07:00:00 -0400

Form 4 Genprex, Inc. For: Feb 27 Filed by: Berger Mark Stanley

Fri, 27 Feb 2026 18:34:00 -0400

si-local-file:///var/storage/secattach/20260227/26084073.html

Form 4 Genprex, Inc. For: Feb 27 Filed by: Berger Mark Stanley

Fri, 27 Feb 2026 18:34:00 -0400

si-local-file:///var/storage/secattach/20260227/26084073.html

Form 4 Genprex, Inc. For: Feb 27 Filed by: Confer Ryan M.

Fri, 27 Feb 2026 18:33:00 -0400

si-local-file:///var/storage/secattach/20260227/26084068.html

Form 4 Genprex, Inc. For: Feb 27 Filed by: Confer Ryan M.

Fri, 27 Feb 2026 18:33:00 -0400

si-local-file:///var/storage/secattach/20260227/26084068.html

Form 8-K Genprex, Inc. For: Feb 23

Mon, 23 Feb 2026 08:08:00 -0400

si-local-file:///var/storage/secattach/20260223/26039701.html

Form 8-K Genprex, Inc. For: Feb 23

Mon, 23 Feb 2026 08:08:00 -0400

si-local-file:///var/storage/secattach/20260223/26039701.html

Genprex receives Japanese and EU patents for cancer gene therapy combinations

Mon, 23 Feb 2026 08:02:56 -0400

Genprex Inc. (NASDAQ: GNPX) announced that the Japanese Patent Office issued a favorable appeal decision to grant a patent for using Reqorsa gene therapy in combination with PD-L1 antibodies to treat cancer. The European Patent Office also issued a decision to grant a patent for combining Reqorsa with PD-1 antibodies for cancer treatment.

The company maintains exclusive licenses to both patents. The Japanese patent covers the Acclaim-3 clinical trial combining Reqorsa gene therapy with Genentech's Tecentriq for treating small cell lung cancer.

"The recent decisions by the Japanese Patent Office and European Patent Office to grant patents for our REQORSA gene therapy

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer

Mon, 23 Feb 2026 08:00:00 -0400